Literature DB >> 27598486

[Neutrophil/lymphocyte ratio in complete blood count as a mortality predictor in breast cancer].

Ximena Mimica1, Francisco Acevedo2, David Oddo3, Carolina Ibáñez4, Lidia Medina2, Alexis Kalergis5, Mauricio Camus1, César Sánchez2.   

Abstract

UNLABELLED: The white blood cell count is one of the most sensitive markers associated with inflammation. The neutrophil/lymphocyte count ratio may be an independent factor for breast cancer mortality. AIM: To assess the predictive value of the neutrophil/lymphocyte ratio for mortality in breast cancer.
MATERIAL AND METHODS: Review of the database of a cancer center of a University hospital. Patients with infiltrating breast cancer treated between 1997 and 2012 were selected. The pathology type and lymph node involvement were obtained from the pathology report. The expression of estrogen, progesterone and Human Epidermal Growth Factor Receptor 2 (HER2) was determined by immunohistochemistry or in situ fluorescent hybridization (FISH). The absolute peripheral neutrophil and lymphocyte counts were obtained from a complete blood count obtained at least three months before treatment. Patients were followed for a median of 61 months (range 1-171).
RESULTS: From 323 eligible patients, after excluding those in stage IV and those without an available complete blood count, 131 patients were analyzed (81 with negative receptors and 117 HER2 enriched). The neutrophil/lymphocyte ratio was similar in both types of tumors (2.1 and 1.91 respectively). Twenty two patients died during follow-up. Surviving patients with HER2 enriched tumors had a lower neutrophil/lymphocyte ratio than those who died (1.79 and 3.21 respectively, p < 0.01). In a multivariate analysis, including age, tumor stage and lymph node involvement as confounding factors, the neutrophil/lymphocyte ratio was still significantly associated with a risk of death with a hazard ratio of 2.56.
CONCLUSIONS: A high neutrophil/lymphocyte ratio in the complete blood count can be a predictor of death in breast cancer.

Entities:  

Mesh:

Year:  2016        PMID: 27598486     DOI: 10.4067/S0034-98872016000600001

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  4 in total

Review 1.  Neutrophils in the Tumor Microenvironment.

Authors:  Lingyun Wu; Sugandha Saxena; Rakesh K Singh
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer.

Authors:  Mauricio Rivas; Francisco Acevedo; Francisco Dominguez; Hector Galindo; Mauricio Camus; David Oddo; Alejandra Villarroel; Dravna Razmilic; Jose Peña; Matias Munoz Medel; Maria Elena Navarro; Alejandra Perez-Sepulveda; Lidia Medina; Tomas Merino; Juan Briones; Alexis Kalergis; Cesar Sanchez
Journal:  Asian Pac J Cancer Prev       Date:  2019-07-01

3.  Development and Validation of a New Multiparametric Random Survival Forest Predictive Model for Breast Cancer Recurrence with a Potential Benefit to Individual Outcomes.

Authors:  Huan Li; Ren-Bin Liu; Chen-Meng Long; Yuan Teng; Lin Cheng; Yu Liu
Journal:  Cancer Manag Res       Date:  2022-03-01       Impact factor: 3.989

4.  Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients.

Authors:  Javier Valdés-Ferrada; Natalia Muñoz-Durango; Alejandra Pérez-Sepulveda; Sabrina Muñiz; Irenice Coronado-Arrázola; Francisco Acevedo; Jorge A Soto; Susan M Bueno; Cesar Sánchez; Alexis M Kalergis
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.